ABS001 / Absco Therapeutics - LARVOL DELTA

ABS001: A Retention-Optimized Intratumoral Immunotherapy Eliciting Robust Innate and Adaptive Responses in HPV and Non-HPV Tumors (SITC 2025) - "However, conventional intratumoral approaches often fail due to rapid drug leakage, insufficient retention, and inadequate immune activation.5 To address these limitations, we developed ABS001, an intratumoral immunomodulatory delivery platform containing imiquimod engineered for prolonged retention, targeted distribution, and sustained immune stimulation across the tumor-immune interface. Importantly, the intermediate dose achieved the most potent immune activation and T cell infiltration into the tumor, underscoring the value of dose optimization. Taken together, these data highlight ABS001's potential as a highly targeted and effective immunotherapy platform for cervical cancer and with potential in other solid tumors with an immunosuppressive microenvironment.Ethics Approval The Animal Use Protocol was approved by SmartLabs' Institutional Animal Care and Use Committee and Institutional Biosafety Committee."

Cervical Cancer • Oncology • Solid Tumor • CD4 • CD8 • CD80 • CD86